EcoDrugPlus

Cholecystokinin B Receptor

Ensembl ID : ENSOCUG00000007797
Gene Symbol: CCKBR
3 Cross references
264 Possible Orthologues:

Cholesteryl Ester Transfer Protein

Ensembl ID : ENSOCUG00000013137
Gene Symbol: CETP
2 Cross references
137 Possible Orthologues:

Cholinergic Receptor Muscarinic 2

Ensembl ID : ENSOCUG00000016569
Gene Symbol: CHRM2
2 Cross references
259 Possible Orthologues:

Cholinergic Receptor Muscarinic 3

Ensembl ID : ENSOCUG00000009346
Gene Symbol: CHRM3
3 Cross references
255 Possible Orthologues:

Cholinergic Receptor Muscarinic 4

Ensembl ID : ENSOCUG00000021064
Gene Symbol: CHRM4
2 Cross references
184 Possible Orthologues:

Cholinergic Receptor Muscarinic 5

Ensembl ID : ENSOCUG00000003930
Gene Symbol: CHRM5
3 Cross references
263 Possible Orthologues:

Cholinergic Receptor Nicotinic Alpha 3 Subunit

Ensembl ID : ENSOCUG00000005023
Gene Symbol: CHRNA3
3 Cross references
207 Possible Orthologues:

Cholinergic Receptor Nicotinic Alpha 4 Subunit

Ensembl ID : ENSOCUG00000002185
Gene Symbol: CHRNA4
3 Cross references
204 Possible Orthologues:

Cholinergic Receptor Nicotinic Alpha 7 Subunit

Ensembl ID : ENSOCUG00000002580
Gene Symbol: CHRNA7
2 Cross references
243 Possible Orthologues:

Coagulation Factor Ii Thrombin Receptor

Ensembl ID : ENSOCUG00000022794
Gene Symbol: F2R
2 Cross references
327 Possible Orthologues:

Coagulation Factor Iii, Tissue Factor

Ensembl ID : ENSOCUG00000004834
Gene Symbol: F3
2 Cross references
243 Possible Orthologues:

Coagulation Factor X

Ensembl ID : ENSOCUG00000022738
Gene Symbol: F10
3 Cross references
237 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).